Analytical Data
-
基因名
BTZ
- Application
-
别名
BTZ；MLN51；Protein CASC3
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O15234
-
表达区间
1-703aa
-
氨基酸序列
MADRRRQRAS QDTEDEESGA SGSDSGGSPL RGGGSCSGSA GGGGSGSLPS QRGGRTGALH LRRVESGGAK SAEESECESE DGIEGDAVLS DYESAEDSEG EEGEYSEEEN SKVELKSEAN DAVNSSTKEE KGEEKPDTKS TVTGERQSGD GQESTEPVEN KVGKKGPKHL DDDEDRKNPA YIPRKGLFFE HDLRGQTQEE EVRPKGRQRK LWKDEGRWEH DKFREDEQAP KSRQELIALY GYDIRSAHNP DDIKPRRIRK PRYGSPPQRD PNWNGERLNK SHRHQGLGGT LPPRTFINRN AAGTGRMSAP RNYSRSGGFK EGRAGFRPVE AGGQHGGRSG ETVKHEISYR SRRLEQTSVR DPSPEADAPV LGSPEKEEAA SEPPAAAPDA APPPPDRPIE KKSYSRARRT RTKVGDAVKL AEEVPPPPEG LIPAPPVPET TPTPPTKTGT WEAPVDSSTS GLEQDVAQLN IAEQNWSPGQ PSFLQPRELR GMPNHIHMGA GPPPQFNRME EMGVQGGRAK RYSSQRQRPV PEPPAPPVHI SIMEGHYYDP LQFQGPIYTH GDSPAPLPPQ GMLVQPGMNL PHPGLHPHQT PAPLPNPGLY PPPVSMSPGQ PPPQQLLAPT YFSAPGVMNF GNPSYPYAPG ALPPPPPPHL YPNTQAPSQV YGGVTYYNPA QQQVQPKPSP PRRTPQPVTI KPPPPEVVSR GSS
-
分子量
76.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BTZ (bortezomib) fusion proteins represent a significant area of research within the field of biotechnology and therapeutics, particularly in the treatment of cancer and autoimmune diseases. Bortezomib, a proteasome inhibitor, has shown efficacy in treating multiple myeloma and certain types of lymphoma by promoting apoptosis in malignant cells. The exploration of BTZ as a fusion protein aims to enhance its therapeutic efficacy and specificity. Researchers are investigating the potential of coupling BTZ with various targeting moieties, such as antibodies or peptides, to create a more selective approach that minimizes off-target effects and reduces toxicity. This strategy may allow for the localized delivery of bortezomib directly to cancer cells, thereby improving treatment outcomes and patient quality of life. Furthermore, the study of BTZ fusion proteins is part of a broader initiative to develop personalized medicine approaches, where therapies can be tailored to the unique molecular profiles of individual patients. As the understanding of cancer biology and the mechanisms of drug action continues to evolve, the development and optimization of BTZ fusion proteins hold promise for more effective and safer treatment options in oncology. This research is critical not only for increasing the therapeutic window of existing treatments but also for discovering new avenues in cancer therapy that could lead to breakthroughs in patient care.
